Cellprothera

CellProthera is the first company to successfully demonstrate primary research in repairing myocardial tissue after acute myocardial infarction (AMI) using autologous CD34+ stem cells. Clinical results show excellent safety and significant clinical benefits. The innovative method developed by CellProthera is considered by experts as one of the most effective approaches for treating AMI and preventing secondary congestive heart failure (CHF).